Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is opinion. Many "facts" haven't played out. Perhaps it is timing, perhaps not.
Funny, CEO doesn't get it either. Hmmm...
Great analogy to Cubs. To bad I am an Indian's fan. :)
Sorry, not an allegation. That is how main stream investor sentiment works.
Well he did say that he's not revealing half the products. You can't put a value on an unknown. When tech is validated by FDA with a stamp of approval some trust will be restored and value given to the known pipeline.
I was hoping that wasn't the case for anyone. I have consistently tried to call out the over exaggerated expectations, but get ridiculed. There will be a positive ending to the story here, but will be much smaller and later than some loud investors here claim.
I find it funny that Nasrat doesn't know why the stock didn't react at the additional details of the FDA meeting. Believe it or not, there is a trust issue with management. Delay after delay, issue after issue. Disappointing revenue. Investors are waiting for approval at this point and are no longer taking management's word on their future outlook. I had to deliver a similar message last week that investors no longer have faith in management of a multi-billion dollar company. Same exact message. Real results need to be seen since investors get burned so many times, eventually there becomes no reliance on future outlook. Trust needs to be rebuilt. Elite has been a struggling "show-me" stock for several years. 2015 was supposed to be breakout year. Then it was 2016. Still nothing yet, but may see some grass shoots in late 2017, but won't be from SequestOx.
Best of luck.
Any specific timing on resubmission and expected review timeframe?
Missing call now, but definitely what I was looking to hear.
I thought there was mention of another company's sales force too, but it may have been related to SunGen opportunities. Puracap update is warranted as Monday may be the last company we receive update prior to SequestOx resubmission.
We also do not have a sales force so Elite revenues would be a fraction from royalties excluding manufacturing benefit.
I am of the opinion that board commentary has zero effect on share price. There is so much garbage on this board to both extremes. For example, this wasn't the worst quarter, but to say it was the best is far from the truth or must be an alternate truth. Results were pretty crappy, at best. Monday's explanation & program updates are where the real value is at.
Cash on hand is not from operations. It is from dilution. Well dilution & selling NOL's this quarter.
I am not going anywhere. I have never sold a single share since first acquiring shares several years ago. I get ticked at some of the misrepresentation that some board members bring that creates a false sense of reality, but staying put. I do worry about further dilution as R&D is as big as we want it to be, but operating cash flow currently is an issue. Ground work is being laid, but not sure it is fast enough. We'll know more on Monday, but will be for sure holding another year, maybe longer.
Not impressed with 6% growth, especially in light of time my from last quarter that should have worked in our favor for higher revs. In the end, I am not here for generics.
At this point Troxyca seemed like a strategic maneuver to slow Elite.
I would read FDA's potential new guidance as a good & bad guy for Elite. If all drugs have to do is prove safety it significantly lowers the hurdle for future competition as well. We are slowly going to be flooding the market with proven goods(safety, efficiency, etc). Will be interesting to see how FDA evolves.
What was so stellar about revenue? It fell from last quarter. Oh and the quarter before. I invest and debate facts. Why is revenue dropping quarter over quarter?
Little higher at 923M shares when include subsequent event. Definitely good news that it has slowed, but getting closer to max authorized.
Where did additional cash come from? Not operations.
Selling NOL's & a little dilution. Dilution severely slowed which is actually fantastic. Hopefully can stop altogether soon.
Wait. Forgot subsequent event. Another 6.6M in dilution.
Let me help you. I believe in the LT prospects, but this quarter as reflected in the financials sucks. PERIOD.
Nice try though.
No momentum in generics. Revenues 6% growth over LY?! 2 straight quarters where rev has dropped. Gross profit was hammered. 3.8M cash bleed.
12M more shares diluted. At least that has slowed down a little.
Selling of NOL's was actually decent as the 8% discount wasn't too bad.
This is reality in black & white for better or worse.
Hoping these results allow more time to buy. :)
Net income is a joke as it was driven by change in FV of derivatives. Has nothing to do with operation. Gross profit got wacked from 60% to 25%. Yikes!!
Completely agree. Will be a fun year to watch execution unfold.
Valid point and will definitely help. I think it will have a much slower ramp than SequestOx though.
We do know the reva this quarter should be really good due to timing of shipments going out fell in this quarter vs last. Last quarter revs were poor sequentially. I am assuming we will realize the timing benefit here.
Don't forget filing of first product with SunGen this year where the smallest market for their products is $500M. 2017 will be setup for next year. I would expect significant investment from proceeds to really get pipeline cooking.
I will eat my shorts on this one. I could have sworn CFO projected mid year CFP. I recall even writing it down in notes. I just went through last 4 transcripts and found wording suggesting getting closer, but also mentioned R&D will be picking up after past quarters were light focusing on generic side. I think you may be right that CFP may not happen until SequestOx launch.
In doing reading, was reminded of many things such as Epic's Oxy IR was launched last year at this time. Also, last Q3 call stated reverse split decision was at least a year away to get to NASDAQ. Looking forward to progress update more than anything.
I will hunt for & post quote from CFO. It is comments like this to which mgmt can be held accountable. Need to hunt for another anyway.
CF positive would be on generics alone that have been growing. I hate to break this news to you. We'll see today if topline grew over prior year & quarter.
Mid year was company's own projection, not mine. This quarter may be one of the last non CFP periods.
I believe they stated last call CF positive by mid year. That was after CRL.
Can't find post on who commented on TA being gagged, but meant to respond. Complete garbage. I am consulting in Investor Relations for a project right now for a multi billion dollar company. No public company that I have ever heard of allows the TA to divulge actual AS or OS intraquarter. This info is posted on the cover pages of the Q & K. Only an issuer (company) can request that data. Not given to anyone else.
So how do they go bankrupt if they are CF positive mid year? Not possible.
Awesome! I thought about college fund for my kids. May wait a couple more months.
Good news is the website uses data from the most recent Q. Bad news is 30% dilution has taken place since Q3 2015 not including upcoming results for which they aren't anticipated to be CF positive quite yet, but hopefully will significantly slow the dilutive bloodbath.
Very interesting. Thanks for sharing.
Prove it with a date where they have done this. That is very unlike their typical cadence.
I could be misremembering, but when has Elite ever released financial results a few days before the call? It is usually day of for afternoon call or after close the preceding day if call is in the morning.
Thanks. Looked like unformatted Excel date.